A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

A man on the Texas 10 Most Wanted Fugitives list was arrested in San Angelo on Feb. 13, according to the Texas Department of ...

They were all managed with inferior meatus microsurgery and nasal endoscopic probing without silicone intubation. After a mean follow-up period of 14.75 (±11.93) months, successful outcomes were ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The saltwater solution will fill your nasal passages and sinuses, cross behind the nasal septum and exit from your lower nostril into the sink. Repeat on the opposite side. Once finished ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

What Happens When the Nasal Septum is Misaligned? When the nasal septum is not properly aligned, it can interfere with normal airflow, resulting in complications like obstructed airflow that may ...

A deviated septum is when the wall that separates your left and right nasal passages is off-center. This makes one nasal air passage smaller than the other and can cause ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...